Overview
Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked leukodystrophy characterized by impaired myelin formation due to defective biosynthesis of proteolipid protein (PLP), leading to progressive neurological deterioration 1.Diagnosis
Biochemical Analysis: Demonstrates absence of proteolipid apoprotein (lipophilin) with residual myelin basic protein and other myelin markers 1.
Neuropathological Examination: Reveals lack of myelin-specific lipids and normal peripheral nervous system 1.
Genetic Testing: Identification of mutations in the PLP gene on the X chromosome can confirm diagnosis 1.Management
Supportive Care: Focuses on managing symptoms and providing neurological support 1.
Physical and Occupational Therapy: To maintain mobility and daily functioning 1.
Seizure Control: Anticonvulsants as needed for seizure management 1.Special Populations
Pediatrics: Early diagnosis and intervention are crucial for managing symptoms and improving quality of life 1.Key Recommendations
Conduct biochemical analysis and genetic testing to confirm the absence of proteolipid apoprotein and identify X-linked mutations in PLP gene for definitive diagnosis (Evidence: Strong 1).
Implement supportive care measures including physical and occupational therapy to enhance functional abilities (Evidence: Moderate 1).
Manage seizures with appropriate anticonvulsant therapy as clinically indicated (Evidence: Expert opinion 1).References
1 Koeppen AH, Ronca NA, Greenfield EA, Hans MB. Defective biosynthesis of proteolipid protein in Pelizaeus-Merzbacher disease. Annals of neurology 1987. link